Behind the markets

Daily Trades

UPDATE: Apellis Pharma (APLS) is still a “BUY”

A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
Learn More

January 2023 Issue: Apellis Pharmaceuticals (SYM: APLS)

An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population). As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
Learn More

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Get Deal

Categories

Behind the Markets

1.7K subscribers

Independent Research for Independent Investors

Behind the Markets
Good morning, everyone! Dylan Jovine here from Behind the Markets. Happy Wednesday—it’s January 22nd, and I hope you’re feeling as optimistic as I am. Yesterday, we hosted an incredible webinar where we discussed the massive opportunities created by Trump’s deregulation policies and their impact on takeovers. This shift is shaping up to be one of the most exciting times for investors looking for unique opportunities. The stock market is at its most expensive point in history—83% pricier than when Clinton took office and even 50% higher than during the roaring 1920s. With valuations so high, traditional trades like AI, quantum computing, or big tech are already priced in. But where others see limitations, we see possibilities. High stock prices, pent-up demand, and cash-rich corporations are creating the perfect storm for a takeover boom. In today’s video, I’ll break down the three key ingredients driving this opportunity and share why I believe companies like Amazon, NVIDIA, and major pharma giants are poised to make major moves. We’re talking about potential triple-digit gains, similar to what we saw in 2018 when the takeover environment last exploded. Join us at Takeover Targets to get ahead of the curve—this is shaping up to be an exciting year for smart investors. Let’s make it happen! ✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼 https://www.youtube.com/channel/UCczJ4YRRQLl6KrH06iapaRw?sub_confirmation=1 ✅ SIGN UP FOR DYLAN'S DIARY HERE 👇🏼👇🏼 https://go.behindthemarkets.com/dylans-diary-sign-up/ ✅ VISIT OUR WEBSITE 👇🏼👇🏼 https://behindthemarkets.com/
YouTube Video VVVjeko0WVJSUUxsNktySDA2aWFwYVJ3LjR6RDhleHJGc2cw

Dylan Jovine | Trump’s Deregulation Fuels Takeover Boom: What Investors Need to Know

✅ REGISTER FOR "The Trump Takeover Summit" WEBINAR HERE 👇🏼👇🏼 https://event.webinarjam.com/channel/trumptakeoversummit Good morning, everyone! Dylan Jovine here from Behind the Markets. Happy Tuesday—it’s January 21st, and we officially have a new president in office. While the peaceful transfer of power is always an incredible moment, what’s even more exciting is the massive investment opportunity this shift represents. Today at 1 PM, we’re hosting a webinar to reveal what I believe is the biggest opportunity of Trump’s presidency: takeovers. With the stock market already near all-time highs and a P/E ratio of 30, the real action isn’t going to come from stocks themselves. Instead, we’re looking at a perfect storm of factors fueling a takeover boom. Corporations are sitting on mountains of cash, pent-up deals have been blocked by the prior administration, and now we have a new, pro-business administration ready to let these deals fly. It’s what Citibank’s Jane Fraser calls “The Big Unlock,” and I couldn’t agree more. In today’s webinar, I’ll share three top takeover targets that could benefit the most under the Trump administration. These companies have been in talks with major players like Amazon, NVIDIA, and Gilead, with offers previously blocked by regulatory hurdles. Now, with fewer restrictions and a more deal-friendly environment, we’re looking at some incredible opportunities for 2025. Make sure you don’t miss this one—it could change the game for your portfolio. I’ll see you at 1 PM! ✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼 https://www.youtube.com/channel/UCczJ4YRRQLl6KrH06iapaRw?sub_confirmation=1 ✅ SIGN UP FOR DYLAN'S DIARY HERE 👇🏼👇🏼 https://go.behindthemarkets.com/dylans-diary-sign-up/ ✅ VISIT OUR WEBSITE 👇🏼👇🏼 https://behindthemarkets.com/
YouTube Video VVVjeko0WVJSUUxsNktySDA2aWFwYVJ3LlpfSnJMYjYxMmpR

Dylan Jovine | Trump’s Pro-Business Agenda Sparks M&A Frenzy—Top Targets Revealed

✅ REGISTER FOR "The Trump Takeover Summit" WEBINAR HERE 👇🏼👇🏼 https://event.webinarjam.com/channel/trumptakeoversummit Good morning, everyone! Dylan Jovine here from Behind the Markets. Today is a special day—Inauguration Day. I’ve always loved a good inauguration speech, from JFK’s inspiring words to Reagan’s bold vision. They remind me of the incredible gift we have in this country: the peaceful transfer of power. It’s a tradition I cherish, and yes, I’ll be forcing my kids to watch it with me later today! But let’s shift gears to something else that has me excited: the current state of Wall Street banks and the massive wave of takeovers coming our way. Last week, the big players—Goldman Sachs, JPMorgan, Morgan Stanley, and others—reported stellar earnings. Their executives are calling this a once-in-a-decade moment for mergers and acquisitions, with multi-billion-dollar deals about to flow like water. They’re even calling it “The Big Unlock.” So, what’s driving this frenzy? Big Pharma is racing to address a looming patent cliff, robotics are being revolutionized by AI, and companies across industries are sitting on a trillion dollars in cash, ready to deploy. Deals in robotics, pharmaceuticals, and energy are about to reshape the market, and we’re positioning ourselves to take advantage. Want to know how? Join our webinar tomorrow, where I’ll reveal my top picks for the most exciting opportunities of 2025. Trust me, you won’t want to miss this. ✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼 https://www.youtube.com/channel/UCczJ4YRRQLl6KrH06iapaRw?sub_confirmation=1 ✅ SIGN UP FOR DYLAN'S DIARY HERE 👇🏼👇🏼 https://go.behindthemarkets.com/dylans-diary-sign-up/ ✅ VISIT OUR WEBSITE 👇🏼👇🏼 https://behindthemarkets.com/
YouTube Video VVVjeko0WVJSUUxsNktySDA2aWFwYVJ3LjYtalM1bEptX3Iw

Dylan Jovine | Wall Street’s 'Big Unlock': The Takeover Wave of 2025

Load More... Subscribe

Recent posts

The Trump Takeover Boom is kicking off now…

How to Trade Trump’s National Energy Emergency

Two Discounted Stocks to Buy Now – 1/20

Wall Street’s “Big Unlock”

Tags

Connect with Us

Icon-facebook Icon-btmshare_tw

UPDATE: Apellis Pharma (APLS) is still a “BUY”

A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
Learn More

January 2023 Issue: Apellis Pharmaceuticals (SYM: APLS)

An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population). As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
Learn More

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
Behind the markets

Company

Explore

CUSTOMER SERVICE

  • We’re here to help.
    Contact Us:
    Mon – Fri | 10 AM – 7 PM EST
  • 1-800-851-1965

© 2025 Behind the Markets, LLC. All rights reserved.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.